Chef Anahita Naderi

CECOFLES to present outcomes of fertility treatment cycles in ASRM Annual Meeting INVO Bioscience.

Dr. Claude Ranoux, president of INVO Bioscience, commented, ‘We look forwards with great anticipation to the CECOFLES presentation regarding the use of INVOcell in its initial treatment cycles. We are assured that INVOcell offers performed well in these initial applications. Additionally, we are delighted that the study results have already been accepted and you will be unveiled at a prestigious meeting the caliber of the ASRM.’.. CECOFLES to present outcomes of fertility treatment cycles in ASRM Annual Meeting INVO Bioscience, Inc.Forteo , in November 2002 was granted FDA approval. It stimulates new bone formation by increasing the quantity and activity of bone forming cells known as osteoblasts. Forteo is accepted for the treatment of osteoporosis in postmenopausal females who are at risky for fracture also to increase bone mass in guys with major or hypogonadal osteoporosis who are at high risk for fracture. Included in these are men with a history of osteoporosis-related fracture, or who’ve multiple risk factors for fracture, or who’ve failed or are intolerant to earlier osteoporosis therapy, based upon physician assessment. Related StoriesElderly females should take more vitamin D supplementation during the wintertime, suggests researchersDoing workout during puberty can improve bone health in adulthood, Spanish research confirmsDiet abundant with soy proteins and isoflavones can protect menopausal ladies from osteoporosisUntil Forteo’s acceptance, the only approved osteoporosis remedies were antiresorptives, which work mainly to gradual or stop bone loss by reducing the number and action of bone-removing cells known as osteoclasts.